Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Cellectis S.A. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 34 | 36 | +2 |
| Shares | 15.2M | 14.0M | −1.19M (−7.8%) |
| Value | $29.3M | $27.6M | −$1.70M (−5.8%) |
New holders (7)
Institutions that held Cellectis S.A. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 29,983 | $59.1K | 0.00% |
| Rhumbline Advisers | 2,970 | $5.85K | 0.00% |
| BNP Paribas Arbitrage, SA | 1,217 | $2.39K | 0.00% |
| Parallel Advisors, LLC | 500 | $984 | 0.00% |
| Russell Investments Group, Ltd. | 98 | $193 | 0.00% |
| Tower Research Capital LLC (TRC) | 45 | $89 | 0.00% |
| Ronald Blue Trust, Inc. | 48 | $0 | 0.00% |
Sold out (5)
Institutions that held Cellectis S.A. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| CVI Holdings, LLC | 129,434 | $249.8K |
| Jane Street Group, LLC | 50,522 | $99.8K |
| Vontobel Holding Ltd. | 30,000 | $57.9K |
| Old Mission Capital LLC | 22,329 | $43.1K |
| UBS Group AG | 330 | $637 |